Evidence map›Paper›PMID 30603278›Full record

ArticleDiabetology international2016

Chronic hyperglycemia may attenuate the serum-uric-acid-lowering effect of low-dose febuxostat in Japanese patients with type 2 diabetes mellitus.

Yukihiro Bando, Hitomi Toyama, Hideo Kanehara, Azusa Hisada, Kazuhiro Okafuji, Daisyu Toya, Nobuyoshi Tanaka

Open access · bronzeAbstract read
In one paragraph

Article in Diabetology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yukihiro BandoDepartment of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, Wadanaka-machi, Fukui, 918-8503 Japan.
Hitomi ToyamaDepartment of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, Wadanaka-machi, Fukui, 918-8503 Japan.
Hideo KaneharaDepartment of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, Wadanaka-machi, Fukui, 918-8503 Japan.
Azusa HisadaDepartment of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, Wadanaka-machi, Fukui, 918-8503 Japan.
Kazuhiro OkafujiDepartment of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, Wadanaka-machi, Fukui, 918-8503 Japan.
Daisyu ToyaDepartment of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, Wadanaka-machi, Fukui, 918-8503 Japan.
Nobuyoshi TanakaDepartment of Internal Medicine, Fukui-ken Saiseikai Hospital, Funabashi 7-1, Wadanaka-machi, Fukui, 918-8503 Japan.
Fukui-ken Saiseikai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study investigated the independent predictors of the serum uric acid (sUA)-lowering effect of low-dose febuxostat, a novel xanthine oxidase inhibitor, in Japanese patients with type 2 diabetes mellitus (T2DM). MATERIALS AND

methodsData of 130 T2DM patients who had been taking febuxostat 10 mg once daily for elevated sUA (≥7 mg/dl) for at least 12 weeks were retrieved from medical records. Spearman's rank correlation coefficients were calculated to determine the correlations between sets of two independent continuous variables. Multiple stepwise linear regression analysis was used to determine independent predictors of the percent change of sUA levels after 12 weeks of febuxostat treatment (%ΔsUA).

resultsAmong all patients, %ΔsUA was significantly correlated with age (

conclusionsHigh HbA

Indexed as

FebuxostatGlycated albuminGlycated hemoglobinSerum uric acidType 2 diabetes

Identifiers

PMID30603278
PMCPMC6224986
OpenAlexW2240082594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.